Skip to main content
SpringerLink
Log in

Übersichtstabellen

  • Chapter
Book cover Neuro-Psychopharmaka Ein Therapie-Handbuch

  • 161 Accesses

Zusammenfassung

In diesen Tabellen sind die in Deutschland (D), Österreich (A) und der Schweiz (CH) im Handel erhältlichen Antidepressiva alphabetisch nach ihren gebräuchlichen Kurzbezeichnungen aufgeführt. Es wurden die in der Roten Liste 2002 verwandten internationalen Freinamen (INN), INNv (vorgeschlagene Freinamen) oder sonstige Kurzbezeichnungen gewählt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 159.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • ALBANI F, RIVA R, BARUZZI A (1995) Carbamazepine clinical pharmacology: a review. Pharmacopsychiatry 28: 235–244

    Article  PubMed  CAS  Google Scholar 

  • ASCI IER JA, COLE JO, COLIN JN et al. (1995) Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56 [Suppl]: 395401

    Google Scholar 

  • AYD FJ (1984) Long-term treatment of chronic depression: 15-year experience with doxepin HCL. J Clin Psychiatry 45: 39–45

    PubMed  Google Scholar 

  • BAKER GB, Courts RT, MCKENNA KF et al. (1992) Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review. J Psychiatr Neurosci 17: 206–214

    CAS  Google Scholar 

  • BALFOUR JA, BRYSON HM (1994) Valproic acid. A review of its pharmacology and therapeutic potential in indications other than epilepsy. CNS Drugs 2: 144–173

    Article  Google Scholar 

  • BALLENGER JC (1996) Clinical evaluation of venlafaxine. J Clin Psychopharmacol 16 [Suppl 3]: 29–36

    Article  Google Scholar 

  • BAN TA, McEvoy JP, WILSON WH (1980) Viloxazine: a review of the literature. Int Pharmacopsychiatry 15: 118–123

    PubMed  CAS  Google Scholar 

  • BARON DP, UNGER HR, WILLIAMS HE et al. (1976) A double blind study of the antidepressants dibenzepin and amitriptyline. NZ Med J 83: 273–274

    CAS  Google Scholar 

  • BERGER M, GASTPAR M (1996) Trimipramine: achallenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci 246: 235–239

    Article  PubMed  CAS  Google Scholar 

  • BREYER-PFAFF U, GIEDKE H, GAERTNER HJ et al.(1989) Validation of a therapeutic plasma level range in amitriptyline treatment of depression. J Clin Psychopharmacol 9: 116–121

    Article  Google Scholar 

  • BRILEY M (1998) Milnacipran, a well-tolerated specific serotonin and norepinephrine re-uptake inhibiting antidepressant. CNS Drug Rev 4: 137–148

    Article  CAS  Google Scholar 

  • BURNETT FE, DINAN TG (1998) Venlafaxine: pharmacology and therapeutic potential in the treatment of depression. Hum Psychopharmacol 13: 153–162

    Article  CAS  Google Scholar 

  • BURROWS GD, MAGUIRE KP, NORMAN TR (1998) Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. J Clin Psychiatry 59 [Suppl 14]: 4–7

    PubMed  CAS  Google Scholar 

  • CALKER D VAN, WALDEN J (Hrsg) (1994) Valproat inder Psychiatrie. Zuckschwerdt, München

    Google Scholar 

  • COWEN PJ (1994) The effect of tryptophan-on brain 5-HT function: a review. Hum Psychopharmacol 9: 371–376

    Article  CAS  Google Scholar 

  • DAVIS R, WILDE MI (1996) Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression. CNSDrugs 5: 389–402

    CAS  Google Scholar 

  • DAVIS R, WHITTINGTON R, BRYSON HM (1997) Ne-fazodone: a review of its pharmacology and clinical efficacy in the management of major depression. Drugs 53: 608–636

    Article  PubMed  CAS  Google Scholar 

  • DELGADO PL, MICHAELS T (1999) Reboxetine: a review of efficacy and tolerability. Drugs Today 35: 725–737

    Article  PubMed  CAS  Google Scholar 

  • DELINI-STULA A (2000) Milnacipran: an antidepressant with dual selectivity of action on nor-adrenaline and serotonin uptake. Hum Psychopharmacol 15: 255–260

    Article  PubMed  Google Scholar 

  • DEMLING J (1993) Mianserin: Pharmakologie and Klinik eines bewährten Antidepressivums. Fortschr Med 111: 47–50

    Google Scholar 

  • DEMLING J (1995) Blickpunkt Doxepin. Aesopus, Basel

    Google Scholar 

  • DONOVON S, DEARDEN L, RICHARDSON L (1994) Thetolerability of dothiepin: a review of clinical studies between 1963 and 1990 in over 13,000 depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 18: 1143–1162

    Article  Google Scholar 

  • DUNNER D, KUMAR R (1998) Paroxetine: a review of clinical experience. Pharmacopsychiatry 31: 89–101

    Article  PubMed  CAS  Google Scholar 

  • FOSTER RH, GOA KL (1997) Paroxetine: a review of its pharmacology and therapeutic potential in the management of panic disorder. CNSDrugs 8: 163–188

    CAS  Google Scholar 

  • FULTON B, MCTAVisH D (1995) Fluoxetine: an overview of its pharmacodynamic and pharmacokinetic properties and review of its therapeutic efficacy in obsessive-compulsive disorder. CNS Drugs 3: 305–322

    Article  Google Scholar 

  • FULTON B, BENFIELD P, CHOUINARD G et al. (1996) Moclobemide: an update of its pharmacological properties and therapeutic use. Drugs 52: 450–474

    Article  PubMed  CAS  Google Scholar 

  • GASTPAR M (Hrsg) (1996) Clomipramin. Bilanz and Perspektive. Thieme, Stuttgart

    Google Scholar 

  • GLEITER CH, VoLz HP (1996) MAO-A inhibitors: state of the art. Expert Opin Invest Drugs 5: 409–419

    Article  CAS  Google Scholar 

  • GRABE HJ, FREYBERGER HJ, MAIER W et al. (1999) In der Anwendung: Opipramol bei somatofor-men Störungen. Nervenheilkunde 18: 571–576

    Google Scholar 

  • GRAM LF (1994) Drug therapy: fluoxetine. N Engl J Med 331: 1354–1361

    Article  PubMed  CAS  Google Scholar 

  • GREn. W, SASSIM N, STROBEL-SASSIM C (1996) Diemanisch-depressive Krankheit: Therapie mit Carbamazepin.

    Google Scholar 

  • Thieme, Stuttgart GREIL W, KLEINDIENST N, ERAZO N et al. (1998) Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 18: 455–460

    Article  Google Scholar 

  • GUELFI JD, DREYFUS JF, DELCROS M, PICHOT P (1983)A double-blind controlled multicenter trial comparing butriptyline with amitriptyline. Neuropsychobiology 9: 142–146

    Article  PubMed  CAS  Google Scholar 

  • GUNASEKARA NS, NOBLE S, BENFIELD P (1998) Parox-etine: an update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs 55: 85–120

    Article  PubMed  CAS  Google Scholar 

  • HE H, RICHARDSON JS (1997) Nefazodone: a review of its neurochemical mechanisms, pharmacokinetics, and therapeutic use in major depressive disorder. CNS Drug Rev 3: 34-48

    Google Scholar 

  • HEGERL U, MOLLER HJ (1996) Nortriptylin: Stellenwert in der psychiatrischen Pharmakotherapie. Psychopharmakotherapie 3: 13–27

    Google Scholar 

  • HOLLIDAY SM, BENFIELD P (1995) Venlafaxine: areview of its pharmacology and therapeutic potential in depression. Drugs 49: 280–294

    Article  PubMed  CAS  Google Scholar 

  • Holm KJ, MARKHAMA (1999) Mirtazapine: a review of its use in major depression. Drugs 57: 607631

    Google Scholar 

  • Houa KJ, SPENCER CM (1999) Reboxetine: a review of its use in depression. CNS Drugs 12: 65–83

    Google Scholar 

  • HOLM KJ, SPENCER CM (2000) Bupropion: a review of its use in the management of smoking cessation. Drugs 59: 1007–1024

    Article  PubMed  CAS  Google Scholar 

  • HOLM KJ, JARVrs B, Fosms RH (2000) Mirtazapine: a pharmacoeconomic review of its use in depression. Pharmacoeconomics 17: 515-534

    Google Scholar 

  • HUYBRECHTS I (1991) The pharmacology of alpra-zolam: a review. Clin Ther 13: 100–117

    PubMed  CAS  Google Scholar 

  • JUNGKUNZ G (1989) Strategien and Hintergründe der medikamentösen Depressionsbehandlung. Stellung des Amitriptylinoxids in der Reihe der Antidepressiva. Vieweg, Braunschweig

    Google Scholar 

  • KASPER S (1995) Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. Int Cl in Psychopharmacol 10 [Suppl 41: 25–35

    Article  Google Scholar 

  • KATZ MM, KosLow SH, MAAS J W et al. (1991) Identifying the specific clinical actions of amitriptyline: interrelationships of behaviour, affect and plasma levels in depression. Psychol Med 21: 599–611

    Article  PubMed  CAS  Google Scholar 

  • KERIHUEL JC, DREYFUS JF (1991) Meta-analyses of the efficacy and tolerability of the tricyclic

    Google Scholar 

  • antidepressant lofepramine. J Int Med Res 19: 183–201

    Google Scholar 

  • KRAVITZ HM, FAweerl J, NEWMAN AJ et al. (1993) Alprazolam and depression: a review of risks and benefits. J Clin Psychiatry 54 [Suppll: 78–84

    Google Scholar 

  • LANCASTER SG, GONZALES JP (1989a) Dothiepin: a review of its pharmacodynamie and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 38: 123–147

    Article  PubMed  CAS  Google Scholar 

  • LANCASTER SG, GoNZAtEs JP (1989b) Lofepramine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 37: 123140

    Google Scholar 

  • LAPIERRE YD (1989) A review of trimipramine: 30 years of clinical use. Drugs 38 [Suppl 11: 17–24

    Article  PubMed  Google Scholar 

  • LAUX G (1995) Kontrollierte Vergleichsstudien mit Moclobemid in der Depressionsbehand-lung. Munch Med Wochenschr 137: 296–300

    Google Scholar 

  • LAUX G, VoLZ HP, MOLLER HJ (1995) Newer and older monoamine oxidase inhibitors. CNSDrugs 3: 145–158

    CAS  Google Scholar 

  • LECRUBIER Y (1994) Risk-benefit assessment of newer versus older monoamine oxidase (MAO) inhibitors. Drug Saf 10: 292–300

    Article  PubMed  CAS  Google Scholar 

  • LEHMANN LS, BOWDEN CL, REDMOND FC et al. (1982)Amitriptyline and nortriptyline response profiles in unipolar depressed patients. Psycho-pharmacology 77: 193–197

    CAS  Google Scholar 

  • LUQuE CA, REY JA (1999) Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother 33: 968–978

    Article  Google Scholar 

  • MAIER W, BENKERT O (1994) Treatment of chronic depression with sulpiride: evidence of efficacy in placebo-controlled single case studies. Psychopharmacology 115: 495-501

    Google Scholar 

  • MCNEELY W, GOA Kt. (1998) Sibutramine: a review of its contribution to the management of obesity. Drugs 56: 1093–1124

    Article  PubMed  CAS  Google Scholar 

  • MCTAVISH D, BENFIELD P (1990) Clomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder. Drugs 39: 136–153

    Article  PubMed  CAS  Google Scholar 

  • MONTGOMERY SA (1998) The place of rehoxetine in antidepressant therapy. J Clin Psychiatry 59 [Suppl 141: 26–29

    PubMed  Google Scholar 

  • MONTGOMERY SA, BULLOCK T, PINDER RM (1991)The clinical profile of mianserin. Nord Psykiat Tidsskr [Suppl 45/241: 27–35

    Google Scholar 

  • MONTGOMERY SA, PROST JF, SOCLES A et al. (1996)Efficacy and tolerability of milnacipran: an overview. Int Clin Psychopharmacol 11 [Suppl 41: 47–51

    Article  PubMed  Google Scholar 

  • MONTGOMERY SA, LOFT H, SANCHEZ C et al. (2001) Escitalopram (S-Enantiomer of Citalopram): Clinical efficacy and onset of action predicted from a rat model. Pharmacology & Toxicology 88: 282–286

    Article  CAS  Google Scholar 

  • MULLER-OERIINGHAUSFN B, GREII. W, BERGHOrER A(Hrsg) (1997) Die Lithiumtherapie. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • MURDOCH D, McTAvLSH D (1992) Sertraline: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. Drugs 44: 604–624

    Article  Google Scholar 

  • NELSON JC (1984) Use of desipramine in de-pressed inpatients. J Clin Psychiatry 45: 10–15

    PubMed  CAS  Google Scholar 

  • NOBLE S, BENFIELD P (1997) Citalopram: a review of its pharmacology, clinical efficacy and tolerability in the treatment of depression. CNS Drugs 8: 410–431

    Article  CAS  Google Scholar 

  • NORMAN TR, BURROWS GD (1995) A risk-benefit assessment of moclobemide in the treatment, of depressive disorders. Drug Saf 12: 46–54

    Article  PubMed  CAS  Google Scholar 

  • PATTEN SB (1992) The comparative efficacy of trazodone and imipramine in the treatment of depression. Can Med Assoc J 146: 1177–1182

    Google Scholar 

  • PERRY CM, BENFIELD P (1997) Sertraline: an overview of its pharmacological properties and a review of its therapeutic efficacy in obsessive-compulsive disorder. CNS Drugs 7: 480–500

    Google Scholar 

  • PINDERRM, BROGDEN RN, SPEIGIITTM et al. (1977)Doxepin up-to-date: a review of its pharmacological properties and therapeutic efficacy with particular reference to depression. Drugs 13: 161–218

    Article  Google Scholar 

  • PINDER RM, BROGDEN RN, SPEIGHT TM et al. (1977) Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs 13: 401–421

    Article  PubMed  CAS  Google Scholar 

  • PRAKASI I A, FOSTER RH (1999) Paroxetine: a review of its use in social anxiety disorder. CNS Drugs 12: 151–169

    Article  Google Scholar 

  • PRESKORN S (1997) Pharmacotherapeutic profile of venlafaxine. Eur Psychiatry 12 [Suppl 41: 285–294

    Article  Google Scholar 

  • RIIFE J, LAUX G, MULLER WE et al. (1997) Sertralin in der Behandlung depressiver Störungen. Psychopharmakotherapie 4 [Suppl] 7l: 18–25

    Google Scholar 

  • RETZOW A, EMRICH HM (1998) Therapie bipolarer affektiver Erkrankungen mit Valproat. Psychiat Prax 25: 163–171

    CAS  Google Scholar 

  • RIEDEL M, MULLER N, MUttER WE, MOLLER HJ (2000) Nefazodon, ein dualserotonerges Antidepressivum. Psychopharmakotherapie 7: 117–124

    Google Scholar 

  • RIEDEL WJ, SCIIOENMAKERS E, VERMEEREN A et al. (1999) The influence of trazodone treatment on cognitive functions in outpatients with major depressive disorder. Hum Psychophar-macol 14: 499–508

    Article  CAS  Google Scholar 

  • RoszINSKY-KdcuER RG, KÖNIG W (1998) Amitriptylinoxid - eine antidepressive Substanz mit kinetischen Besonderheiten. In: BAROCKA A (Hrsg) Psychopharmakotherapie in Klinik und Praxis. Schattauer, Stuttgart, S 111–115

    Google Scholar 

  • RUFHER E, DEGNER D, MÜNZEL U et al. (1999) Antidepressant action of sulpiride. Results of a placebo-controlled double-blind trial. Pharmacopsychiatry 32: 127–135

    Article  Google Scholar 

  • SALLEE FR, PoLLOCK BG (1990) Clinical pharmacokinetics of imipramine and desipramine. Clin Pharmacokinet 18: 346–364

    Article  PubMed  CAS  Google Scholar 

  • SCHOU M (1997) Lithium-Behandlung der manisch-depressiven Krankheit. Thieme, Stuttgart

    Google Scholar 

  • SPENCER CM, WILDE MI (1998) Milnacipran: a review of its use in depression. Drugs 56: 405–427

    Article  PubMed  CAS  Google Scholar 

  • SPERLING W, DEMLIN GJ (1996) Das therapeutischeSpektrum von Imipramin und Clomipramin. Nervenheilkunde 15: 178–183

    Google Scholar 

  • SPERLING W, DEMLING J (1998) Die Therapie mit Trin¨²pramin. In: BAROCKA A (Hrsg) Psychopharmakotherapie in Klinik und Praxis. Schattauer, Stuttgart, S 116–122

    Google Scholar 

  • STEVINSON C, ERNST E (1999) Hypericum for depression: an update of the clinical evidence. Eur Neuropsychopharmacol 9: 501–505

    Article  PubMed  CAS  Google Scholar 

  • STILLE G (Hrsg) (1986) Dosulepin. Zuckschwerdt, München STOKES PE, HOL.TZ A (1997) Fluoxetine tenth anniversary update: the progress continues. Clin Titer 19: 1135–1150

    Article  Google Scholar 

  • TAN JY, LEVIN GM (1999) Citalopram in the treatment of depression and other potential uses in psychiatry. Pharmacotherapy 19: 675–689

    Article  PubMed  CAS  Google Scholar 

  • VIEWEG WV (1998) Nefazodone and depression. Drugs Today 34: 845–853

    PubMed  CAS  Google Scholar 

  • VoLZ HP (1997) Controlled clinical trials of hypericum extracts in depressed patients: an overview. Pharmacopsychiatry 30 [Suppll: 72–76

    Google Scholar 

  • Votz HP, MOLLER HJ (1998) Opipramol bei Angst-und Somatisierungsstörungen. Fortschr Neu-rol Psychiat 66: S21–S24

    Article  Google Scholar 

  • WAGNER W, PLEKKENPOL B, GRAY TE et al. (1992) Review of tluvoxamine safety database. Drugs 43 [Suppl 21: 48–54

    Google Scholar 

  • WAGNER W, ZABORNY BA, GRAY TE (1994) Fluvox-amine: a review of its safety profile in worldwide studies. Int Clin Psychopharmacol 9: 223–227

    Article  PubMed  CAS  Google Scholar 

  • WELLS BG, GELENBERG AJ (1981) Chemistry, pharmacology, pharmacokinetics, adverse effects, and efficacy of the antidepressant maprotiline hydrochloride. Pharmacotherapy 1: 121–139

    PubMed  CAS  Google Scholar 

  • WHEATLEY D (1998) Hypericum extract: potential in the treatment of depression. CNS Drugs 9: 431–440

    Article  Google Scholar 

  • WILDE MI, WHITTINGTON R (1995) Paroxetine: a pharmacoeconomic evaluation of its use in depression. Pharmacoeconomics 8: 62–81

    Article  PubMed  CAS  Google Scholar 

  • WILDE MI, BENFIELD P (1998) Fluoxetine: a pharmacoeconomic review of its use in depression. Pharmacoeconomics 13: 543–561

    Article  PubMed  CAS  Google Scholar 

  • WILDE MI, PLOSKFR GL, BENFIELD P (1993) Fluvoxamine: an updated review of its pharmacology, and therapeutic use in depressive illness. Drugs 46: 895–924

    Article  PubMed  CAS  Google Scholar 

  • YOUNG SN (1991) Use of tryptophan in combination with other antidepressant treatments: a review. J Psychiatr Neurosci 16: 241–246

    CAS  Google Scholar 

Download references

Authors
  1. O. Dietmaier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Laux
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinische Neurochemie, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universität Würzburg, Bundesrepublik Deutschland

    Peter Reiderer

  2. Bezirksklinikikum Gabersee, Ludwig-Maximilians-Universität München, Wasserburg a. Inn, Bundesrepublik Deutschland

    Gerd Laux

  3. Wien, österreich

    Walter Pöldinger

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag/Wien

About this chapter

Cite this chapter

Dietmaier, O., Laux, G. (2002). Übersichtstabellen. In: Reiderer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka Ein Therapie-Handbuch. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6150-0_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6150-0_16

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-83647-7

  • Online ISBN: 978-3-7091-6150-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation